MUKILTEO, Wash., June 3, 2009 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) today announced that the validation study performed by its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), in collaboration with the Department of Pathology at the University of Texas Health Science Center in San Antonio, TX (UTHSCSA) is available as an advance online publication in the official journal of the United States and Canadian Academy of Pathology (USCAP), Modern Pathology.
